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SUMMARY
Despite the fact that eﬂornithine was considered as the safer drug to treat human African trypanosomiasis (HAT) and has
been freely available since 2001, the diﬃculties in logistics and cost burden associated with this drug meant that the toxic
melarsoprol remained the drug of choice. TheWorldHealth Organization responded to the situation by designing amedical
kit containing all the materials needed to use eﬂornithine, and by implementing a training and drugs distribution
programmewhich has allowed a transition to this much safer treatment. The introduction of the combination of nifurtimox
and eﬂornithine (NECT) has accelerated the shift from melarsoprol to the best treatment available, due to reduced dosage
and treatment time for eﬂornithine that has signiﬁcantly lessened the cost and improved the burden of logistics encountered
during treatment and distribution. The decrease in the use of more dangerous but cheaper melarsoprol has meant a rise in
the per patient cost of treating HAT. Although NECT is cheaper than eﬂornithine monotherapy, an unexpected
consequence has been a continuing rise in the per patient cost of treating HAT. The ethical decision of shifting to the best
available treatment imposes a ﬁnancial burden on HAT control programmes that might render long-term application
unsustainable. These factors call for continuing research to provide new safer and more eﬀective drugs that are simple to
administer and cheaper when compared to current drugs.
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INTRODUCTION
By the end of the last century a growing number
of cases of human African trypanosomiasis (HAT)
were not responding to the old and far from ideal
drugs available to treat HAT (Legros et al. 1999).
Moreover, the production of some drugs was
threatened, either by increasing price (pentamidine),
halted production (eﬂornithine) or planned cessation
of production (nifurtimox, suramin andmelarsoprol)
(Van Nieuwenhove, 2000). No new drugs were in the
pipeline.
This review gives a comprehensive summary of the
process followed to ensure availability of drugs for
the treatment of HAT and the eﬀorts to ensure the
access of patients to the best treatment. The ﬁnancial
burden of such ethical decision is discussed.
ACCESS TO TREATMENT
The World Health Organization created in 1999 a
network to ensure availability and aﬀordability of
anti-trypanosomal drugs and started a joint advocacy
campaign with the newly established Campaign for
Access to Essential Medicines and Médecins Sans
Frontières (MSF) to secure and maintain trypano-
cidal drug production. As a result, in 2001, the two
manufacturers Aventis and Bayer committed not
only to ensure manufacture but also to donate the
drugs to the World Health Organization for free
distribution.
However, whilst discussing the chemotherapy of
HAT throughout the ﬁrst years of the 21st century,
several commentators have complained about the
primacy of the use of melarsoprol to treat second-
stage gambiense HAT. The major issue being
melarsorpol’s unacceptable toxicity whilst the less
toxic, albeit cumbersome to administer, eﬂornithine
has been available for over 20 years (Chappuis et al.
2005; Balasegaram et al. 2006; Robays et al. 2008;
Priotto et al. 2008).
Indeed, the choice of drug to treat HAT depends
on the subspecies of trypanosome and the stage of
the disease, as judged by results of a diagnostic
lumbar puncture to determine whether parasites have
become manifest within the central nervous system.
However, the logistics and ﬁnancial capacity of
the national sleeping sickness control programmes
(NSSCPs) and the technical level of staﬀ responsible
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for administering treatment also impact greatly
on local drug policy. Therefore, even though
eﬂornithine, considered as the safer drug to treat
HAT, was made freely available in 2001, the
diﬃculties in logistics (each patient requiring huge
doses of drug delivered in 56 infusions over 14 days
in 14 litres of sterile saline) meant that melarsoprol
remained the drug of choice in spite of its toxicity:
a 5% drug-induced death rate through reactive
encephalopathy (Blum et al. 2001; Seixas, 2004;
Burri, 2010). The fact that treatment failures had
reached levels of 30% in some foci in Angola, the
Democratic Republic of the Congo, South of Sudan
and Uganda (Moore, 2005) compounded the short-
comings of melarsoprol as a drug. The World Health
Organization responded to the situation by designing
a medical kit containing all the materials needed
to use eﬂornithine in a logistically simpliﬁed fashion.
Furthermore the organization supported a vigorous
programme of capacity building and drug distri-
bution to ensure that HAT victims had access to
the best treatment available.
However, the implementation of eﬂornithine as
ﬁrst-line treatment was accompanied by a number of
concerns. The drug is trypanostatic, it has a short
half-life in the body and the diﬃcult administration
schedule imposes the risk of insuﬃcient compliance
to the full treatment course. Furthermore, eﬂor-
nithine resistance is easily selected in the laboratory
(Vincent et al. 2010). Then the risk of inducing
resistance to eﬂornithine in the ﬁeld, in addition to
existing melarsoprol resistance, could lead to the
emergence of untreatable second-stage HAT. It
therefore became essential to determine whether
combination therapies might improve eﬃcacy and
reduce the risk of resistance (Moore, 2005).
Clinical trials were conducted to assess eﬃcacy of
combinations of eﬂornithine, melarsoprol and nifur-
timox, a drug labelled to be used in treating Chagas’
disease, with some reported eﬃcacy in second-stage
HAT (Janssens and De Muynck, 1977; Moens et al.
1984; Pepin et al. 1992). In each case combinations
yielded improved eﬃcacy although all combinations
including melarsoprol retained unacceptable drug
toxicity (Priotto et al. 2006; Bisser et al. 2007;
Checchi et al. 2007).
Based on the preliminary data obtained during
these clinical trials, a multicentre, randomized, non-
inferiority clinical trial comparing eﬂornithine
monotherapy with the combination of nifurtimox
and eﬂornithine (NECT) was conducted between
2003 and 2008. The study concluded that the
combination of nifurtimox and eﬂornithine had
a comparable safety and eﬃcacy with eﬂornithine
monotherapy. Furthermore, the combination al-
lowed for reduced dose and treatment time for
eﬂornithine which signiﬁcantly lessened the cost
and signiﬁcantly improved the logistical burden for
treatment and distribution (Priotto et al. 2009).
These positive results led to the WHO Expert
Committee on the Selection and Use of Essential
Medicines (held in March 2009) to recommend the
inclusion of nifurtimox in theModel List of Essential
Medicines (EML) to be used in combination with
eﬂornithine for the treatment of the second-stage of
Trypanosoma brucei gambiense infection (World
Health Organization, 2009).
Following this inclusion, NECT was proposed as
the best available therapeutic option to treat the
second-stage of gambiense HAT. The World Health
Organization secured a gratis donation of nifurtimox
through an agreement with Bayer to match the
gratis donation of eﬂornithine by Sanoﬁ-Aventis.
Inﬂuenced by the impact of the kit for eﬂornithine
the World Health Organization also designed a new
medical kit containing the combination in an easily
accessible form and facilitated the training of key staﬀ
in disease endemic countries (DECs) to implement
the drug combination.
For the ﬁrst-stage disease, fortunately, in spite of
the drugs having been used for over 70 years and
requiring parenteral administration, similar safety
and eﬃcacy concerns have not yet emerged.
Unfortunately to treat the second stage of rhode-
siense HAT, melarsoprol remains the only drug
available. This article presents the relative rates of
use of available drugs to treat the second stage of
gambiense HAT which accounts for 99·9% of the
second stage of HAT cases reported in 2010 (World
Health Organization, unpublished data) and discusses
about the ﬁnancial and social consequences.
THE PROCESS IN FACILITATING THE ACCESS
TO THE BEST TREATMENT
Eﬂornithine has been donated to the World Health
Organization since 2001 following an agreement
between the manufacturer and WHO and has been
provided free of charge to DECs. Its better safety
proﬁle, when compared to melarsoprol, rendered it
the best treatment, in principle, for second-stage
gambiense HAT. However, its use as a ﬁrst-line
treatment was restricted to relatively wealthy non-
governmental organizations (NGOs) because even
when available free of charge due to its cumbersome
and logistically demanding administration regime
it proved prohibitively burdensome. Therefore only
the small fraction of cases detected by NGOs had
access to eﬂornithine while most of the cases detected
byNSSCPs continued to be treated with melarsoprol
(Simarro et al. 2011). Only some NSSCPs could
aﬀord its use but in these cases its use was generally
reserved for melarsoprol refractory cases. For these
reasons during the period 2001–2006 only a modest
rise in use of eﬂornithine was recorded; an average
12% of all second-stage gambiense HAT cases
detected during the period were treated with eﬂor-
nithine (Fig. 1).
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In 2006, the World Health Organization was asked
by representatives of the DECs for support with
logistics and training, to allow NSSCPs to switch
from melarsoprol to eﬂornithine as the ﬁrst-line
treatment. A training course was therefore organized
for key staﬀ from DECs to train in the adminis-
tration of eﬂornithine and also to teach others how to
administer the drug (Simarro et al. 2011).Moreover, a
pre-packaged medical kit containing all the necessary
drugs, infusion materials and accessories to adminis-
ter 2 eﬂornithine treatments was designed. The kit’s
weight was 40 kg, its volume 190 dm3 and its cost
€1107 including transport to health facilities in the
HAT foci, making the cost of a single eﬂornithine
treatment an estimated €554 (2010 prices).
In 2007, thanks to the enhanced number of trained
technicians capable of administering treatment
and the freely available medical kits, most NSSCPs
switched to eﬂornithine as the ﬁrst-line treatment
in their HAT treatment policies. As a consequence,
second-stage HAT gambiense cases treated with
eﬂornithine increased by 167% (Fig. 1).
This new trend was reﬂected in a change in the
distribution of recipients of eﬂornithine. From 2001
to 2006 the NGOs were the major recipients of
distributed eﬂornithine, accounting for 89% of all
used drug, while the NSSCPs only used 11%. By
contrast, over the period 2007–2009 the NSSCPs
become the major consumers, using 65% of the total
distributed eﬂornithine while the NGOs accounted
for 35% (Simarro et al. 2011).
The inclusion of NECT in the EML in 2009
was followed by rapid addition of the combination
therapy in the treatment policy of the NSSCPs.
Previous eﬀorts to encourage the implementation
of eﬂornithine created a network of staﬀ already
trained in the required diﬃcult parenteral infusion
and management of the drug. Since use of NECT
is also substantially less complex than eﬂornithine
monotherapy (14 eﬂornithine infusions are given
twice a day over 7 days, with associated oral
nifurtimox during 10 days – as opposed to 56 in-
fusions given 4 times a day over 14 days), the
widespread uptake of NECT has been rapid. The
World Health Organization continues to provide,
in a new medical kit format, all the necessary drugs,
infusion materials and accessories required to admin-
ister NECT. The reduced dosing of eﬂornithine
means that the new medical kit for NECT, with the
same volume as the eﬂornithine kit, now includes
suﬃcient material for 4 treatments, weight 38 kg
and costs €1152. The cost of 1 NECT treatment is
therefore estimated at €288 (2010 prices) including
transport to health facilities in the HAT foci.
As a result, in 2010, the use of melarsoprol has
fallen to a historical low of just 12% of cases treated
due to a larger use of melarsoprol alternative drugs
(Fig. 1). In 2010 eﬂornithine monotherapy still
accounted for 29% of treatments whereas NECT
was the therapeutic regime of choice, used to treat
59% of all second-stage gambiense HAT cases
reported that year.
THE FINANCIAL BURDEN OF ACCESS TO THE
BEST TREATMENT
Historically, treatment of second-stage HAT has
been considered a paradigm of dangerous drug usage
when melarsoprol was the only available drug. The
5% fatality rate associated with adverse events was
considered as the ‘price to pay’ to avoid the 100%
death rate from infection. The cost of ancillary drugs
in the case of reactive encephalopathy during the use
of melarsoprol was estimated as 20–50 USD (Robays
et al. 2008). Ethically it is of paramount importance
that people aﬀected by HAT can access the best
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Fig. 1. Rate use of anti-trypanocidal drugs to treat second-stage gambiense HAT, 2001–2010. (NECT-EML: year
when NECT was included in the Essential Medicines List of WHO).
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treatment. However, fulﬁlling this prerogative carries
ﬁnancial consequences.
In 2001, 16614 second stages of gambiense HAT
were reported (World Health Organization, unpub-
lished data); 97% of them were treated with melarso-
prol, the most toxic but least expensive drug available
(Fig. 1). The average cost to treat 1 second-stage
gambiense HAT patient was €28 (Fig. 2). Over the
period 2001–2009 the use of less toxic but more
expensive eﬂornithine increased 21-fold from 3%
to 64% (Fig. 1). Consequently, the average of cost
of treating 1 second-stage gambiense HAT case over
this period increased 11 times from €28 to €317
(Fig. 2).
In 2010, despite the implementation of NECT
which is almost half the cost of the treatment
with eﬂornithine (€288 versus €554), the average
cost per second-stage gambiense HAT case treated
has continued to rise reaching €336 (Fig. 2). Given
that NECT is signiﬁcantly cheaper than eﬂornithine
monotherapy this appears surprising at ﬁrst.
However, the improved rate of uptake of NECT
and consequent reduction in use of the far cheaper
melarsoprol explains why (Fig. 1). This increased
cost has had an impact on the distribution of the
WorldHealthOrganization resources, made available
mainly by Sanoﬁ-Aventis, to support HAT control.
From 2001 to 2005, €4386000 (26% of the resources)
where dedicated to the access to treatment and 64245
patients were treated. From 2006 to 2010, €6712300
(60% of the resources) were allocated for access to the
best treatment and 28064 patients were treated.
The shift from melarsoprol to eﬂornithine
(in monotherapy and then as part of the NECT
combination) has resulted in much safer treatment.
Clearly, issues other than the simple cost per patient
should inﬂuence policymaking. For example, in 2001
the number of deaths related to treatment toxicity
was estimated at 830 (5% of cases treated) while in
2010 the number of deaths reported to be related to
drug toxicity was 32 (0·9% of cases treated). To date,
health economists have not attempted to estimate the
ﬁnancial value of a human life, nor the relative value
of the life of a sleeping sickness victim compared to
others. Ethically, such calculations represent a huge
challenge.
DISCUSSION
The development and implementation of NECT for
HAT therapy has been proposed to carry 4 advan-
tages over eﬂornithine monotherapy: (i) the combi-
nation is easier to administer and this has to lead to
a wider use and consequent decrease in patients
exposed to toxic melarsoprol. (ii) the combination
is less expensive including anti-trypanosome and
ancillary drugs, reducing the cost of the treatment
compared with eﬂornithine monotherapy (iii) the
combination is also considered to be less expensive
for the patient due to the short time required in
hospital reducing for the patient and the attendant
the time out of the family environment and (iv) use in
combination should diminish the risk of emergence
of resistance to eﬂornithine. This latter point will
only become clear in time. After 1 year of implemen-
tation of NECT the ﬁrst proposed advantage has
been demonstrated to be true. In 2010 we witnessed
the lowest rate of melarsoprol use in second-stage
gambiense HAT since records began. The second
proposed advantage, however, appears to be con-
founded by an epidemiological and strategic detail
that escaped initial prediction. Although the indi-
vidual per-patient cost is 48% lower when using the
combination NECT instead of eﬂornithine mono-
therapy, the average cost for treating second-stage
gambiense HAT cases over the whole continent
continued to increase by 6%. This has led to the
highest average cost per second-stage gambiense
HAT ever. This apparent paradox is due to the
ethical decision to use the safest but substantially
more expensive alternative therapy NECT as a ﬁrst-
line treatment.
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Fig. 2. Average cost to treat a second-stage gambiense HAT patient, 2001–2010.
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National programmes have been able to select
quality of treatment more than cost-eﬀectiveness
based on purely economical aspects. The added value
in terms of decreased numbers of HAT patients
exposed to and dying from melarsoprol toxicity,
together with the lowering of adverse eﬀects linked
to treatment, and subsequent decrease in satellite
treatment costs associated with those side-eﬀects
is great. NECT receives much better patient com-
pliance and fewer patients abscond. Furthermore,
health staﬀ also suﬀer less stress than when admin-
istering melarsoprol. Unfortunately, it is diﬃcult to
attach a price to these beneﬁts.
In spite ofNECT’s superiority in terms of safety, it
is also important to remember that it is still far from
ideal as a therapy. It still has to be administered by
infusion over a protracted period, carries toxicity
risks mainly fever, seizures and infections (Priotto
et al. 2009). It is logistically diﬃcult to deliver to and
tomanage in the settings in which it is required due to
its parenteral administration and its volume. Above
all, however, the logistical and ﬁnancial burden that
the therapy imposes on HAT control programmes
will become a major issue and might render long-
term application unsustainable. These two major
negative factors call for continuing research to over-
come these obstacles providing not only new safer
and more eﬀective drugs but also drugs which are
simple to administer and cheaper when compared to
current drugs.
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